Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GETZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1508866443
CMS profile
249750
Location
WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,512.52

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,190.58 56
Education $321.94 4

By paying entity

PY2021 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GETZ

NPI 1508866443 · CMS profile ID 249750

Allopathic & Osteopathic Physicians / Dermatology

WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 60 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1508866443?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $1,512.52 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $18.3312/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918203 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $2.6312/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918201 CMS
Janssen Biotech, Inc. $99.9912/16/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331101 CMS
Janssen Biotech, Inc. $14.5012/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331105 CMS
AbbVie Inc. $90.2612/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581277 CMS
Regeneron Healthcare Solutions, Inc. $6.2412/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580373 CMS
PFIZER INC. $26.8712/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833112069 CMS
Janssen Biotech, Inc. $6.6712/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331099 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $23.7011/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918205 CMS
UCB, Inc. $39.0511/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807423997 CMS
UCB, Inc. $8.6611/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807423991 CMS
Janssen Biotech, Inc. $4.7211/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331097 CMS
Novartis Pharmaceuticals Corporation $23.8311/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812690973 CMS
Janssen Biotech, Inc. $9.7311/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331103 CMS
AbbVie Inc. $17.5910/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581269 CMS
AbbVie Inc. $2.0210/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581273 CMS
UCB, Inc. $1.3210/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807331491 CMS
UCB, Inc. $11.7510/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807466189 CMS
UCB, Inc. $42.6610/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807331881 CMS
Janssen Biotech, Inc. $91.6210/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331109 CMS
Novartis Pharmaceuticals Corporation $34.2610/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812690967 CMS
Janssen Biotech, Inc. $18.8010/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331107 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.1610/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918209 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $0.7310/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918211 CMS
PFIZER INC. $23.1410/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832931865 CMS
PFIZER INC. $0.9210/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833182435 CMS
AbbVie Inc. $6.5709/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581265 CMS
Regeneron Healthcare Solutions, Inc. $7.9609/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580369 CMS
Regeneron Healthcare Solutions, Inc. $80.0009/15/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580371 CMS
AbbVie Inc. $6.4409/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581261 CMS
AbbVie Inc. $6.9008/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581257 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $20.5108/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918215 CMS
Novartis Pharmaceuticals Corporation $20.5308/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812690971 CMS
UCB, Inc. $5.6208/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807406687 CMS
Janssen Biotech, Inc. $21.7808/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331083 CMS
Regeneron Healthcare Solutions, Inc. $25.3008/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580367 CMS
Amgen Inc. $125.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 860922437 CMS
UCB, Inc. $122.9808/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807451247 CMS
Janssen Biotech, Inc. $8.6407/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331081 CMS
AbbVie Inc. $6.2407/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581253 CMS
AbbVie Inc. $6.6307/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794581249 CMS
Regeneron Healthcare Solutions, Inc. $6.6906/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580365 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $22.2606/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851918217 CMS
Novartis Pharmaceuticals Corporation $19.7906/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812690969 CMS
Janssen Biotech, Inc. $8.1306/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331079 CMS
Janssen Biotech, Inc. $18.2706/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331095 CMS
Mission Pharmacal Company $13.2006/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 754275300 CMS
Janssen Biotech, Inc. $2.8206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788331093 CMS
UCB, Inc. $38.6105/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807361071 CMS
Regeneron Healthcare Solutions, Inc. $23.4405/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809580363 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,203.48 19
PY2020 $161.56 8
PY2021 $1,512.52 60
PY2022 $1,032.69 42
PY2023 $888.03 32
PY2024 $985.47 43
PY2025 $621.06 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,013.60 1
PY2025 Principal investigator $446,834.92 130
PY2024 Recipient $7,087.86 1
PY2024 Principal investigator $650,362.14 156
PY2023 Recipient $10,934.40 2
PY2023 Principal investigator $209,903.19 44
PY2022 Principal investigator $139,606.12 29
PY2021 Recipient $11,617.83 3
PY2021 Principal investigator $358,649.13 52
PY2020 Principal investigator $277,127.30 39
PY2019 Principal investigator $329,491.24 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

39 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $3,617.25 12/30/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721202555
Principal investigator 1 PFIZER INC. $602.56 12/26/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742896405
Principal investigator 1 AbbVie Inc. $1,577.00 11/30/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721197163
Principal investigator 1 PFIZER INC. $2,000.00 10/29/2020 Non-covered Recipient Entity
Dundee Dermatology
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 742925405
Principal investigator 1 PFIZER INC. $4,462.50 10/28/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742925407
Principal investigator 1 PFIZER INC. $2,500.00 10/21/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN ATOPIC DERMATITIS PATIENTS No dispute reported 06/30/2026 742925413
Principal investigator 1 AbbVie Inc. $6,308.00 09/30/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721187979
Principal investigator 1 PFIZER INC. $25.00 09/30/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742871023
Principal investigator 1 PFIZER INC. $92.00 09/30/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742871381
Principal investigator 1 PFIZER INC. $6,400.00 09/15/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742925411
Principal investigator 1 PFIZER INC. $25.00 08/31/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742870999
Principal investigator 1 PFIZER INC. $92.00 08/31/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742871325
Principal investigator 1 AbbVie Inc. $1,419.50 08/28/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721182839
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $28,847.85 08/12/2020 Non-covered Recipient Entity
Dundee Dermatology
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736759759
Principal investigator 1 PFIZER INC. $92.00 07/31/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742870995
Principal investigator 1 PFIZER INC. $25.00 07/31/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742871025
Principal investigator 1 AbbVie Inc. $2,839.00 07/30/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721177525
Principal investigator 1 PFIZER INC. $9,000.00 07/29/2020 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742947795
Principal investigator 1 AbbVie Inc. $2,839.00 07/01/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721173893
Principal investigator 1 AbbVie Inc. $1,798.25 05/29/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721168565
Principal investigator 1 PFIZER INC. $70.00 05/08/2020 Non-covered Recipient Entity
Dundee Dermatology
AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOSEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 742879255
Principal investigator 1 PFIZER INC. $1,786.06 04/30/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742969263
Principal investigator 1 AbbVie Inc. $3,596.50 04/29/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721162685
Principal investigator 1 PFIZER INC. $11,448.44 04/28/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742969269
Principal investigator 1 AbbVie Inc. $3,596.50 03/27/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721157327
Principal investigator 1 Amgen Inc. $5,283.00 03/20/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 731639933
Principal investigator 1 Novartis Pharmaceuticals Corporation $50,703.81 03/17/2020 Non-covered Recipient Entity
PAUL GETZ MD SC DUNDEE DERMATOLOGY
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 721494579
Principal investigator 1 PFIZER INC. $1,895.72 03/17/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742969266
Principal investigator 1 Amgen Inc. $1,500.00 03/12/2020 Non-covered Recipient Entity
PAUL GETZ MD SC
A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 731624691
Principal investigator 1 Celgene Corporation $1,500.00 03/12/2020 Non-covered Recipient Entity
Dr Paul Getz
A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 736448587
Principal investigator 1 PFIZER INC. $24,889.87 02/27/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742969261
Principal investigator 1 PFIZER INC. $11,364.80 02/27/2020 Non-covered Recipient Entity
Dundee Dermatology
JAK1 DUPILUMAB COMPARATOR STUDY No dispute reported 06/30/2026 742970473
Principal investigator 1 PFIZER INC. $6,720.00 02/25/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742968949
Principal investigator 1 AbbVie Inc. $2,411.50 02/18/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721150825
Principal investigator 1 Amgen Inc. $26,401.00 01/30/2020 Non-covered Recipient Entity
PAUL GETZ MD SC DBA DUNDEE DERMATOLOGY
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 731640039
Principal investigator 1 AbbVie Inc. $3,617.25 01/21/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
M15-997 No dispute reported 06/30/2026 721146019
Principal investigator 2 E.R. Squibb & Sons, L.L.C. $31,903.56 01/20/2020 Non-covered Recipient Entity
Dundee Dermatology
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod No dispute reported 06/30/2026 736759761
Principal investigator 1 Amgen Inc. $6,728.27 01/08/2020 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 731639939
Principal investigator 1 PFIZER INC. $7,149.11 01/07/2020 Non-covered Recipient Entity
Dundee Dermatology
PHASE 2AB SAFETY AND EFFICACY STUDY OF PF06700841 IN PATIENTS WITH MODERATE PSORIASIS No dispute reported 06/30/2026 742901475